FDA Mission, Legal Authority, and Jurisdiction

The U.S. Food and Drug Administration operates as the primary federal regulatory body responsible for protecting public health through the oversight of a product portfolio that spans pharmaceuticals, biologics, medical devices, food, cosmetics, tobacco, and veterinary products. This page explains the statutory foundations of FDA authority, the structural boundaries that define its jurisdiction, and the persistent tensions between regulatory mandate and operational constraint. Understanding these foundations is essential for manufacturers, researchers, healthcare professionals, and policymakers who interact with FDA-regulated products.

• Definition and Scope
• Core Mechanics or Structure
• Causal Relationships or Drivers
• Classification Boundaries
• Tradeoffs and Tensions
• Common Misconceptions
• Checklist or Steps (Non-Advisory)
• Reference Table or Matrix

Definition and Scope

The FDA's formal mission is defined in 21 U.S.C. § 393 as protecting and promoting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices, and by ensuring the safety of the nation's food supply, cosmetics, and products that emit radiation. That statutory language translates into jurisdiction over approximately 20 cents of every dollar spent by American consumers, a scope estimate cited by the FDA itself (FDA Economic Impact, FDA.gov).

The agency operates as a component of the Department of Health and Human Services (HHS) and derives its authority from a cluster of major statutes rather than a single organic act. The Federal Food, Drug, and Cosmetic Act (FD&C Act) of 1938 remains the foundational instrument, supplemented by the Public Health Service Act (PHS Act), which governs biologics, and the Family Smoking Prevention and Tobacco Control Act of 2009, which created the Center for Tobacco Products.

For a comprehensive overview of how these mandates relate to each other at the program level, the FDA Mission and Authority reference page provides supporting context.

Core Mechanics or Structure

FDA authority operates through three primary legal mechanisms: pre-market review, post-market surveillance, and enforcement action.

Pre-market review requires manufacturers to demonstrate safety and, where applicable, efficacy before a product reaches commerce. The standard applied varies by product category: new drugs require substantial evidence of efficacy under 21 U.S.C. § 355, whereas Class I medical devices may require only general controls with no pre-market submission. Biologics require a Biologics License Application (BLA) under 21 C.F.R. Part 601.

Post-market surveillance obligations include mandatory adverse event reporting (21 C.F.R. Part 803 for devices; 21 C.F.R. Part 314.81 for drugs) and periodic safety update reporting. FDA's MedWatch program accepts voluntary submissions from healthcare practitioners and patients.

Enforcement authority includes warning letters, injunctions, seizures, consent decrees, and criminal referrals. Civil money penalties under the FD&C Act can reach $15,000 per violation and $1,000,000 per proceeding for certain violations (21 U.S.C. § 333).

The agency is organized into product-specific centers — including the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), the Center for Devices and Radiological Health (CDRH), and the Center for Food Safety and Applied Nutrition (CFSAN) — each administering its portion of the statutory framework. A detailed breakdown of center-level responsibilities appears at FDA Centers and Offices.

Causal Relationships or Drivers

FDA's regulatory architecture reflects a direct legislative response to documented public health failures. The 1938 FD&C Act emerged after the sulfanilamide disaster of 1937, in which diethylene glycol used as a solvent in a liquid antibiotic formulation caused 107 deaths (FDA History, FDA.gov). The 1962 Kefauver-Harris Amendments, which introduced the efficacy requirement for new drugs, followed the thalidomide crisis in Europe. The 1906 Pure Food and Drug Act, the original precursor statute, passed in part due to public response to Upton Sinclair's 1906 exposé of meatpacking conditions and Harvey Wiley's advocacy through the Bureau of Chemistry.

Each statutory expansion follows a pattern: a high-profile failure generates Congressional pressure, which produces new statutory authority, which the agency then implements through notice-and-comment rulemaking under the Administrative Procedure Act (APA), 5 U.S.C. § 553. This reactive legislative pattern means FDA's jurisdiction tends to expand incrementally rather than through comprehensive reform.

For historical context on how these legislative responses shaped the agency's current structure, the FDA History and Milestones page traces the chronological development of statutory authority from 1906 forward.

Classification Boundaries

FDA jurisdiction is bounded by product category, interstate commerce requirements, and concurrent authority held by other agencies. Key boundary conditions include:

Interstate commerce: FDA authority under the FD&C Act applies to products in or affecting interstate commerce. Products manufactured and sold entirely within a single state may fall outside federal jurisdiction, though most supply chains trigger the interstate nexus.

Concurrent and shared jurisdiction: The Drug Enforcement Administration (DEA) controls scheduling of controlled substances under the Controlled Substances Act independently of FDA approval status. The USDA Food Safety and Inspection Service (FSIS) holds primary jurisdiction over meat, poultry, and processed egg products — not FDA. Alcohol falls under the Alcohol and Tobacco Tax and Trade Bureau (TTB) for labeling and the FDA for safety when found in foods not classified as beverages.

Cosmetics versus drugs: The FD&C Act defines a drug by its intended use — to diagnose, cure, mitigate, treat, or prevent disease, or to affect the structure or function of the body. A product marketed with drug claims is regulated as a drug regardless of its physical form. A moisturizer becomes a drug if labeled with claims about altering skin cell turnover. This boundary generates persistent enforcement action.

Dietary supplements: Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), manufacturers are not required to demonstrate safety or efficacy to FDA before marketing, reversing the pre-market review burden that applies to drugs. Structure/function claims are permitted without FDA approval, but disease claims are prohibited and trigger drug classification.

Tradeoffs and Tensions

Speed versus safety: Pre-market review requirements are designed to prevent unsafe products from reaching patients, but review timelines impose delay. The Prescription Drug User Fee Act (PDUFA) system, first enacted in 1992, introduced user fees paid by industry to fund additional review staff and meet statutory performance goals. Critics argue this creates a structural conflict of interest; proponents note that PDUFA-funded review capacity enables median total approval times that shortened from 30 months in the early 1990s to approximately 10 months by the 2010s (FDA Drug Approval Performance Reports).

Innovation versus regulatory certainty: Accelerated approval pathways — including Breakthrough Therapy Designation, Accelerated Approval, and Priority Review — reduce time-to-approval for serious conditions using surrogate endpoints. The tradeoff is reliance on endpoints that may not predict clinical benefit, leading to post-approval confirmatory trial requirements that are not always completed on schedule. The FDA Accelerated Approval Pathways page covers the mechanics of these programs.

Preemption versus state authority: FDA approval of a drug or device label can preempt state tort claims based on failure-to-warn, as addressed in Riegel v. Medtronic, 552 U.S. 312 (2008) for Class III PMA devices. For drugs, Wyeth v. Levine, 555 U.S. 555 (2009) held that failure-to-warn claims against brand-name manufacturers are generally not preempted because manufacturers can update labels unilaterally. The boundary between federal preemption and state liability creates ongoing litigation and compliance uncertainty.

Common Misconceptions

Misconception: FDA approval means a product is risk-free.
Correction: FDA approval means the agency has determined that benefits outweigh known risks at the time of approval for the indicated population. Post-approval safety signals can result in label modifications, Risk Evaluation and Mitigation Strategies (REMS), or market withdrawal. Approval is a probabilistic regulatory determination, not a guarantee.

Misconception: FDA tests products directly in its own laboratories before approval.
Correction: For new drugs and biologics, FDA reviewers evaluate data submitted by sponsors — including clinical trial data, manufacturing data, and preclinical studies. FDA does conduct some independent laboratory testing, particularly for biologics (lot-release testing) and during inspections of manufacturing facilities, but the primary evidentiary base is sponsor-submitted.

Misconception: FDA regulates all health products sold in the United States.
Correction: USDA/FSIS regulates meat, poultry, and processed egg products. The Federal Trade Commission (FTC) regulates advertising claims for many FDA-regulated products, including dietary supplements and OTC drugs, under the FTC Act. EPA regulates pesticide residues in food under the Federal Insecticide, Fungicide, and Rodenticide Act, though FDA enforces tolerances at the product level. Health insurance products, hospital accreditation, and scope of medical practice are state-regulated.

Misconception: The FDA can require drug manufacturers to produce sufficient supply.
Correction: FDA lacks direct authority to compel production volume. Its drug shortage management tools — outlined at FDA Drug Shortage Management — are primarily informational and facilitative rather than compulsory. Mandatory production orders are not within FDA's statutory toolkit under the FD&C Act.

Checklist or Steps (Non-Advisory)

The following sequence describes the statutory and procedural elements that constitute a standard new drug application review cycle under 21 C.F.R. Part 314:

1. Pre-IND meeting — Sponsor requests a Type B meeting with CDER to align on development program expectations before filing an Investigational New Drug (IND) application.
2. IND filing — Sponsor submits IND under 21 C.F.R. § 312.23; FDA has 30 days to place a clinical hold or the study may proceed.
3. Phase 1–3 clinical trials — Conducted under IND oversight; annual reports required; safety reporting obligations apply throughout.
4. Pre-NDA meeting — Sponsor and FDA confirm submission format, content, and outstanding issues.
5. NDA submission — Sponsor files under 21 C.F.R. § 314.50; FDA has 60 days to file or refuse to file.
6. PDUFA review clock — Standard review: 10-month PDUFA goal from date of filing; priority review: 6-month goal.
7. Advisory committee (if convened) — Public meeting with external expert panel; recommendation is non-binding but publicly influential.
8. Complete Response Letter (CRL) or Approval Action — FDA issues approval or identifies deficiencies requiring sponsor response.
9. Post-marketing commitments — Labeling agreed; post-marketing studies and REMS (if applicable) formalized in approval letter.

Reference Table or Matrix

The breadth of this statutory table illustrates why navigating FDA's authority requires product-